Nrg-Hn007-An Open-Label, Phase III Study Of Platinum-Gemcitabine With Or Without Nivolumab In The First-Line Treatment Of Recurrent Or Metastatic Nasopharyngeal Carcinoma
Posted Date: May 5, 2021
- Investigator: Muhammad Riaz
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The primary purpose of this study is to compare the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places in the body (metastatic). The primary outcome measured will be overall survival.
Criteria:
Pathologically (Histologically Or Cytologically) Proven Diagnosis Of Npc That Has Recurred At Locoregional And/Or Distant Sites, Ecog Of 0-1, Adequate Organ Function Per Protocol. No Other Malignancy Within 3 Years, No Past Or Current Medical Disease Or Infection That May Impact A Patient's Ability To Adhere To Study Treatment, No Prior Anti-Cancer Treatment, No History Of Severe (Grade 3-4) Hypersensitivity Reaction To Any Monoclonal Antibody Including Nivolumab And/Or Any Of Its Excipients
Keywords:
Head And Neck Cancer, Nasopharyngeal
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com